Not analysed yet
We haven’t published our own analysis of this CVE. If a person reviews it, this page will say what’s affected and what has to be true for it to matter.
Severity and exploitation
| Score | Rating | CVSS | Vector | Source |
|---|---|---|---|---|
| 8.7 | High | 4.0 | CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N | CNA (VulnCheck) |
- CISA KEV Not listed.
- EPSS 0.0057, the 47th percentile, on 17 Nov 2026: FIRST’s estimate of the chance of exploitation in the next 30 days.
Timeline
Sources
References from the CNA
- www.mayurik.com/source-code/P0349/best-pharmacy-billing-software-free-download
- github.com/nu11secur1ty/CVE-nu11secur1ty/tree/main/vendors/mayuri_k/2022/dawa-pharma-1.0-2022
- www.nu11secur1ty.com/
- www.vulncheck.com/advisories/dawa-pharma-10-sql-injection-via-email-parameter
- www.exploit-db.com/exploits/51818